Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2018 - 11 - 09
点击次数: 0
Positions:
Company: President and CEO of Shanghai Henlius Biotech Inc.
个人简介:
Dr. Scott Liu, President and CEO of Shanghai Henlius Biotech Inc., has a Ph.D. degree in biology from Purdue University.  He also had a postdoctoral training in biology at Stanford University, and later studied business administration (iMBA courses) at Syracuse University.  Dr. Liu has many years of experience in management and leadership.  He has previously served as a VP of R&D of United Biomedical, the fouding director of the Biologics QC department of Bristol-Myers Squibb-Syracuse, and the QAL (QC) director of Amgen-Fremont.  Dr. Liu was a key member of the CMC teams for the late-phase development and commercial cGMP manufacturing of Orencia and Vectibix.  Because of his outstanding achievement, Dr. Liu has won the Bristol-Myers Squibb Company's Tech Ops President Award.  Liu Scott has 21 years of experience in biopharmaceutical R&D, regulatory affairs and quality operations, and he was awarded the title of "1000 Expert of Shanghai" in 2013.  At the same time, Dr. Liu assisted the formation of“Quality Alliance of Protein Therapeutics”and helped the CDE of CFDA in the establishment and improvement of the quality standards for protein therapeutics in China.  He also took the lead to promote an industry-wide adoption of single-use technologies into clinical and commercialization of manufacturing of monoclonal antibody drugs; and actively participated in the development of 《Technical Guidelines of Biosimilar Development and Evaluation》to promote the innovation and globalization of the biopharmaceutical industry of China.  Under his leadership, Henlius has successfully developed and moved into clinical trials six mAb therapeutics (including one innovative mAb), and the first two of which are in phase 3 trials.  Henlius has also successfully built a commercial biologics manufacturing facility in Shanghai in 2016, and obtained an EU QP’s declaration of GMP for conducting the clinical trials of its first four biosimilar products in Europe.
发布时间: 2018 - 11 - 09
点击次数: 0
Positions:
Company: Fosun Kite Biotechnology Co. Ltd
个人简介:
Richard received degrees of B.S of Cell Biology from the University of Science & Technology of China, Ph.D of Molecular Biology from the University of Maryland, Baltimore, and MBA from Xavier University, Cincinnati in the US. He obtained his post-doctoral training at the National Institutes of Health, Baltimore, USA.  Richard now is the CEO of Fosun Kite Biotechnology. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients.  Richard is very experienced in biopharmaceutical industry. Having spent close to 20 years in R&D and management positions in both the US and China, he has taken senior roles and increasing leadership responsibilities in Procter & Gamble Pharmaceutical, Bristol-Myers Squibb in the US, AstraZeneca Innovation Center and GSK R&D Center in China. Prior to Fosun Kite, Richard was the Chief Operation Officer of Cellular Biomedicine Group (NASDAQ: CBMG), where he was in charge of the company’s immunotherapy pipeline including manufacturing, clinical development and registration, and the stem cell business unit.
发布时间: 2018 - 11 - 09
点击次数: 0
Positions:
Company: Lilly Oncology Discovery China/Asia
个人简介:
Dr. Xiang S Ye is executive director of Lilly Oncology Discovery China/Asia. Dr. Ye joined Eli Lilly in early 1998. At Lilly, Dr. Ye led discovery research efforts for novel cancer drugs targeting cancer cell cycle and signaling and delivered 8 clinical candidates, including abemaciclib, a CDK4/6 inhibitor, designated as a breakthrough medicine, and approved by FDA in 2017. In 2008, Dr. Ye served as an Enduring Team Leader and led a group of scientists across the drug R&D value chain in a corporate initiative to speed up drug development and had the responsibility in managing a LO to Phase II portfolio. The team delivered 4 clinical candidates, 2 IND and a Phase II milestones. Dr. Ye has published more than 60 scientific papers and book chapters. Dr. Ye was relocated to Shanghai in 2011 to lead Lilly Oncology Discovery China/Asia and delivered the first clinical candidate in early 2014 from China discovery research. In his current role, Dr. Ye also supervised postdoctoral scientists in China, served as corporate supervisor at Shanghai Science and Technology University, and has leadership roles in several pre-competitive consortia programs, and industry and academic collaborations to promote cancer research and drug development in China/Asia.
发布时间: 2018 - 11 - 09
点击次数: 0
Positions:
Company: WuXi AppTec
个人简介:
Dr. Qunsheng Ji is VP at WuXi AppTec. He currently leads Oncology & Immunology Unit, which provides scientific solutions and services to enable cancer drug discovery and development via platforms of CRISPR gene editing, Immuno-oncology, targeted oncology and biomarker.Prior to WuXi, Dr. Ji was Director of Translational Science, and Head of Bioscience at AstraZeneca Innovation Center China. Based in Shanghai, he was one of the pioneers who contributed to shaping and expanding the center. He also led the effort to reshape AstraZeneca’s global translational science strategy for oncology, established translational research capabilities and delivered innovative candidate drugs.Before joined AstraZeneca, Dr. Ji gained 10 years of biotech experience in drug discovery with Onyx Pharmaceuticals and OSI Pharmaceuticals in the US, where he led a number of drug discovery projects. He received his Ph.D from Peking Union Medical College and Vanderbilt University in the US. He has published over 40 scientific papers in peer-reviewed journals.Currently he also services as Vice Chairman of Sino Drug Discovery Association (SDDA) and member of Bayhelix.